HD-OPM Archive
Hashtags

#sglt2

16 posts

Dapagliflozin linked to lower heart failure risk in carriers of cardiomyopathy variants

Jun 13, 2026 · Louis Nervegna ♥ 5 · 💬 1 Heart rhythm & heart failure

Louis shares a Nature Medicine study of over 12,000 adults with type 2 diabetes in which dapagliflozin was associated with significantly lower heart failure risk in those carrying inherited cardiomyopathy-related variants. Fox News describes an 8-fold reduction in heart failure hospitalization, and suggests genetic screening could eventually guide early treatment.

ARPA-H PROSPR program ($144M) funds first phase 3 aging trials of three drugs

May 20, 2026 · Louis Nervegna ♥ 9 Aging & longevity

Eric Verdin's shared post says ARPA-H awarded $144 million to seven teams to lay groundwork for human aging trials, including a phase 3 in healthy adults in their 60s testing rapamycin, an SGLT2 inhibitor and semaglutide. The key gap is a validated aging biomarker regulators accept. Louis adds that age is the biggest CVD risk factor.

Heart failure in 2026: SGLT2 inhibitors foundational, HFpEF now treatable, early GDMT

Mar 29, 2026 · Louis Nervegna ♥ 4 Heart rhythm & heart failure

A Cardiophilia summary of the latest heart failure evidence update lists several shifts: SGLT2 inhibitors are foundational across the ejection fraction spectrum, HFpEF now has options (finerenone, GLP-1 and incretin therapies), guideline therapy starts in-hospital, decongestion becomes guided by urine sodium, and devices are integrated into care.